Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease.
Hamzah Abu-Sbeih,David M Faleck,Biagio Ricciuti,Robin B Mendelsohn,Abdul R Naqash,Justine V Cohen,Maclean C Sellers,Aanika Balaji,Guy Ben-Betzalel,Ibraheim Hajir,Jiajia Zhang,Mark M Awad,Giulia C Leonardi,Douglas B Johnson,David J Pinato,Dwight H Owen,Sarah A Weiss,Giuseppe Lamberti,Mark P Lythgoe,Lisa Manuzzi,Christina Arnold,Wei Qiao,Jarushka Naidoo,Gal Markel,Nick Powell,Sai-Ching J Yeung,Elad Sharon,Michael Dougan,Yinghong Wang AMERICAN JOURNAL OF GASTROENTEROLOGY（2020）
摘要
Preexisting IBD increases the risk of severe GI adverse events in patients treated with immune checkpoint inhibitors.
更多查看译文
关键词
immune checkpoint inhibitor therapy,inflammatory bowel disease
AI 理解论文
溯源树
样例
